These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32535223)

  • 1. Lycopene in protection against obesity and diabetes: A mechanistic review.
    Zhu R; Chen B; Bai Y; Miao T; Rui L; Zhang H; Xia B; Li Y; Gao S; Wang XD; Zhang D
    Pharmacol Res; 2020 Sep; 159():104966. PubMed ID: 32535223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinnamaldehyde in diabetes: A review of pharmacology, pharmacokinetics and safety.
    Zhu R; Liu H; Liu C; Wang L; Ma R; Chen B; Li L; Niu J; Fu M; Zhang D; Gao S
    Pharmacol Res; 2017 Aug; 122():78-89. PubMed ID: 28559210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvia miltiorrhiza in diabetes: A review of its pharmacology, phytochemistry, and safety.
    Jia Q; Zhu R; Tian Y; Chen B; Li R; Li L; Wang L; Che Y; Zhao D; Mo F; Gao S; Zhang D
    Phytomedicine; 2019 May; 58():152871. PubMed ID: 30851580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive review on the phytochemistry, pharmacokinetics, and antidiabetic effect of Ginseng.
    Liu Y; Zhang H; Dai X; Zhu R; Chen B; Xia B; Ye Z; Zhao D; Gao S; Orekhov AN; Zhang D; Wang L; Guo S
    Phytomedicine; 2021 Nov; 92():153717. PubMed ID: 34583224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating into anti-cancer potential of lycopene: Molecular targets.
    Qi WJ; Sheng WS; Peng C; Xiaodong M; Yao TZ
    Biomed Pharmacother; 2021 Jun; 138():111546. PubMed ID: 34311540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes mellitus, inflammation, obesity: proposed treatment pathways for current and future therapies.
    Sonnett TE; Levien TL; Gates BJ; Robinson JD; Campbell RK
    Ann Pharmacother; 2010 Apr; 44(4):701-11. PubMed ID: 20233909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Mechanisms of the Anti-Obesity and Anti-Diabetic Properties of Flavonoids.
    Kawser Hossain M; Abdal Dayem A; Han J; Yin Y; Kim K; Kumar Saha S; Yang GM; Choi HY; Cho SG
    Int J Mol Sci; 2016 Apr; 17(4):569. PubMed ID: 27092490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G-Protein-Coupled Estrogen Receptor (GPER) and Sex-Specific Metabolic Homeostasis.
    Sharma G; Prossnitz ER
    Adv Exp Med Biol; 2017; 1043():427-453. PubMed ID: 29224106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus.
    Dostálová I; Haluzíková D; Haluzík M
    Physiol Res; 2009; 58(1):1-7. PubMed ID: 19331512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Target for Concurrent Management of Diabetes and Obesity-Related Cancer.
    Wang Q; Imam MU; Yida Z; Wang F
    Curr Pharm Des; 2017; 23(25):3677-3688. PubMed ID: 28677503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of all-trans and cis-isomers of lycopene.
    Boileau TW; Boileau AC; Erdman JW
    Exp Biol Med (Maywood); 2002 Nov; 227(10):914-9. PubMed ID: 12424334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lycopene attenuates body weight gain through induction of browning via regulation of peroxisome proliferator-activated receptor γ in high-fat diet-induced obese mice.
    Zhu R; Wei J; Liu H; Liu C; Wang L; Chen B; Li L; Jia Q; Tian Y; Li R; Zhao D; Mo F; Li Y; Gao S; Wang XD; Zhang D
    J Nutr Biochem; 2020 Apr; 78():108335. PubMed ID: 31978713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of lycopene in cancer, cardiovascular, and neurodegenerative diseases: An update on epidemiological and mechanistic perspectives.
    Saini RK; Rengasamy KRR; Mahomoodally FM; Keum YS
    Pharmacol Res; 2020 May; 155():104730. PubMed ID: 32126272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catalpol in Diabetes and its Complications: A Review of Pharmacology, Pharmacokinetics, and Safety.
    Bai Y; Zhu R; Tian Y; Li R; Chen B; Zhang H; Xia B; Zhao D; Mo F; Zhang D; Gao S
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31514313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural compound renews hope for diabetes and obesity therapeutic target.
    Merk D; Schubert-Zsilavecz M
    Future Med Chem; 2015; 7(7):833-5. PubMed ID: 26061101
    [No Abstract]   [Full Text] [Related]  

  • 16. Adiponectin homolog novel osmotin protects obesity/diabetes-induced NAFLD by upregulating AdipoRs/PPARα signaling in ob/ob and db/db transgenic mouse models.
    Ahmad A; Ali T; Kim MW; Khan A; Jo MH; Rehman SU; Khan MS; Abid NB; Khan M; Ullah R; Jo MG; Kim MO
    Metabolism; 2019 Jan; 90():31-43. PubMed ID: 30473057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Berberine and lycopene as alternative or add-on therapy to metformin and statins, a review.
    Hedayati N; Oskouei Z; Tabeshpour J; Naeini MB
    Eur J Pharmacol; 2021 Dec; 913():174590. PubMed ID: 34801530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (all-E)- and (5Z)-Lycopene Display Similar Biological Effects on Adipocytes.
    Fenni S; Astier J; Bonnet L; Karkeni E; Gouranton E; Mounien L; Couturier C; Tourniaire F; Böhm V; Hammou H; Landrier JF
    Mol Nutr Food Res; 2019 Mar; 63(5):e1800788. PubMed ID: 30512227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lycopene: a review of its potential as an anticancer agent.
    Bhuvaneswari V; Nagini S
    Curr Med Chem Anticancer Agents; 2005 Nov; 5(6):627-35. PubMed ID: 16305484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity.
    Sasaoka T; Wada T; Tsuneki H
    Pharmacol Ther; 2006 Dec; 112(3):799-809. PubMed ID: 16842857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.